RE:Auxly Cannabis Apr 2019 Investor PresentationNot much info in there either.
They really seem to be pinning there hopes on Dosecann being a big player and finding distribution for Inervell.
One good thing with thare price being where it is, warrents and Options will not likely get exerciesed meaning less dilution. Howerver witht he convertable debentures have a strike price of $1.55 it is looking like they may need to dome up with some money to repay that debt which could mean significant further diliusion.
It woudl sure be nice for them to give some guidance on what they expect revenues to be in 2019. From what I gather they are basically going to be shipping most of the product they get to Dosecann to create products for sale in Oct 2019 and beyond, which means six more months of little to no revenue. I thought they would be selling this product for a profit originally, but that does not seem to be the case. Not sure where this stock will end up if they put out three more quarterly reports with less then $1,000,000 in revenues.